Population clinical pharmacology of children: general principles
- PMID: 16807730
- DOI: 10.1007/s00431-006-0188-y
Population clinical pharmacology of children: general principles
Abstract
Introduction: Population modelling using mixed-effects models provides a means to study variability in drug responses among individuals representative of those for whom the drug will be used clinically.
Discussion: The advantages of these models in paediatric studies are that they can be used to analyse sparse data, sampling times are not crucial and can be fitted around clinical procedures and individuals with missing data may still be included in the analysis. The introduction of explanatory covariates explains the predictable part of the between-individual variability. Simulations using parameter estimates and their variability can be used to investigate large numbers of children--many more than is possible in studies dealing with real children--for a fraction of the cost, which is an advantage when developing clinical trials. Paediatric population modelling has expanded greatly in the past decade and is now a routine procedure during the development and investigation of drugs. Children have benefitted and will continue to benefit from this approach.
Similar articles
-
Population clinical pharmacology of children: modelling covariate effects.Eur J Pediatr. 2006 Dec;165(12):819-29. doi: 10.1007/s00431-006-0189-x. Epub 2006 Jun 29. Eur J Pediatr. 2006. PMID: 16807729 Review.
-
Facilitation of drug evaluation in children by population methods and modelling.Clin Pharmacokinet. 2008;47(4):231-43. doi: 10.2165/00003088-200847040-00002. Clin Pharmacokinet. 2008. PMID: 18336053 Review.
-
Pharmacokinetics and population pharmacokinetics in pediatric oncology.Pediatr Blood Cancer. 2020 Apr;67(4):e28132. doi: 10.1002/pbc.28132. Epub 2019 Dec 25. Pediatr Blood Cancer. 2020. PMID: 31876123 Review.
-
Minutes from the round table held in Paris on July 6, 2007: 'Contribution of modelling in the paediatric drug development'.Fundam Clin Pharmacol. 2008 Dec;22(6):609-12. doi: 10.1111/j.1472-8206.2008.00653.x. Fundam Clin Pharmacol. 2008. PMID: 19049663
-
Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.J Pharm Sci. 1996 Jun;85(6):600-7. doi: 10.1021/js9504705. J Pharm Sci. 1996. PMID: 8773956
Cited by
-
Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.Br J Clin Pharmacol. 2017 Mar;83(3):593-602. doi: 10.1111/bcp.13134. Epub 2016 Nov 6. Br J Clin Pharmacol. 2017. PMID: 27641003 Free PMC article. Clinical Trial.
-
Model Based Evaluation of Hypersensitivity Adverse Drug Reactions to Antimicrobial Agents in Children.Front Pharmacol. 2021 Apr 30;12:638881. doi: 10.3389/fphar.2021.638881. eCollection 2021. Front Pharmacol. 2021. PMID: 33995043 Free PMC article. Review.
-
Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux.BMC Pediatr. 2016 Jul 13;16:90. doi: 10.1186/s12887-016-0630-x. BMC Pediatr. 2016. PMID: 27412521 Free PMC article. Clinical Trial.
-
Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: external model evaluation and simulations.Clin Pharmacokinet. 2009;48(7):477-87. doi: 10.2165/11313400-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19691369
-
Covariates of intravenous paracetamol pharmacokinetics in adults.BMC Anesthesiol. 2014 Sep 13;14:77. doi: 10.1186/1471-2253-14-77. eCollection 2014. BMC Anesthesiol. 2014. PMID: 25342929 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous